Thirteen ingredients. Five mechanisms. All peer-reviewed.
The evidence architecture behind the Welyon HP Stack — our multi-mechanism regimen, still in development — as a self-directed guide you can start today. Source the ingredients yourself, build the stack on your own terms. The branded HP Stack follows in 2026.
Standard antibiotic regimens hit one or two pathways — antimicrobial pressure and, with bismuth, some biofilm disruption. H. pylori's documented defenses go further: biofilm formation, efflux-pump activity, and dormant "persister" sub-populations that single- or dual-pathway regimens don't address. The HP Stack is built around five simultaneous mechanistic targets, each backed by peer-reviewed research and most hit by multiple independent pathways — a depth of specificity we haven't found in any commercial supplement formula.
On the evidence: each ingredient has independent peer-reviewed support for its mechanism, but the stack as a combined architecture has no controlled-trial data yet — and we say so throughout the guide.
We're working to change that: the HP Stack will be enrolled in a pre-registered observational study before commercial release, with endpoints and analysis plan fixed in advance.
Antibiotic eradication has the established evidence base. The HP Stack is designed as a complement — or a route for patients who have failed eradication, cannot tolerate antibiotics, or want to try a supplement-based path first.
Standard therapy also carries real trade-offs: antibiotic-associated side effects including nausea, diarrhea, and dysgeusia (a persistent metallic or bitter taste) are common; compliance is a documented challenge; and first-course eradication rates in clinical practice typically range from 70–87% depending on regimen and local resistance patterns.
The core stack contains thirteen ingredients, sourced independently across multiple suppliers. That is a real commitment — in cost, in logistics, and in daily pill burden. We are direct about this in the guide.
The Welyon HP Stack will solve this: a single optimised formulation with standardised ingredient forms, third-party GMP certification, and simplified dosing. The DIY guide is the bridge while that product is in development.
The five mechanisms below represent the documented resistance and persistence strategies of H. pylori that the peer-reviewed literature identifies as clinically relevant. The HP Stack addresses each — in most cases via multiple independent ingredient pathways, not a single agent.
H. pylori forms protective biofilms on the gastric mucosa that shield organisms from antibiotic and immune exposure. Standard bismuth provides partial disruption. The stack targets matrix dissolution via multiple pathways.
Direct antimicrobial activity against H. pylori via multiple ingredient pathways — each with independent peer-reviewed evidence for bacteriostatic or bactericidal effect at relevant doses.
Bacterial efflux pumps are a documented mechanism of acquired antibiotic resistance in H. pylori. The stack includes inhibitors to preserve antimicrobial concentration at the organism — a target standard regimens do not address.
A subset of organisms enter metabolically quiescent states — "persisters" — that standard antibiotic regimens do not fully clear. The stack addresses this sub-population via pathways active against dormant organisms.
Eradication is one outcome; mucosal recovery is another. The stack supports gastric barrier integrity, inflammation resolution, and downstream nutritional pathways the literature has implicated in H. pylori-associated conditions.
Standard antibiotic eradication is the established first-line intervention and the benchmark against which everything else is measured. The HP Stack does not replace that evidence base — it addresses the mechanisms standard therapy does not target, and provides an option for patients where standard therapy has failed or is not appropriate.
A complete guide covering every ingredient in the core stack — the mechanism it targets, the peer-reviewed evidence behind it, the form and dose to look for, and sourcing guidance. Evidence-graded throughout using Welyon's three-tier rubric.
Written for the reader who has tested positive and wants to act with the same rigour as the investigation guides — not a supplement catalogue, but a structured clinical rationale for each component.
Get the HP Formulary · $39 →$39 USD · Guide · Instant access · 14-day refund window
The same three-tier evidence rubric applied across the investigation guides is applied to every ingredient in the HP Stack. Not every ingredient has the same evidence weight — and the guide does not pretend otherwise.
Multiple peer-reviewed studies demonstrating the mechanism at relevant doses. Consistent findings across independent research groups.
Peer-reviewed evidence supporting the mechanism, with some limitations in study size, design, or consistency across the literature.
Early or limited evidence. The mechanism is plausible and documented, but the literature base is not yet sufficient to make strong claims.
The HP Formulary is available now — the full evidence architecture as a self-directed guide, instant access, $39. The branded Welyon HP Stack, with every active pre-formulated, follows in 2026.
If you have already tested positive and want to act now, the investigation guides cover the eight documented conditions and the questions worth raising with a provider of your choosing.
No obligation. Unsubscribe at any time.